ArticleDermatology and therapy2026
Lipidomic Insights into Seborrheic Dermatitis: Clinical Evaluation of Sebum Changes Using SpiderMass.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06578962 (Evaluation of the Effects of Shampoo RV3438G in Recurrent Squamous States and Maintenance of the Effects), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Effects of Shampoo RV3438G in Recurrent Squamous States and Maintenance of the Effects
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeborrheic dermatitis (SD) is a skin disorder in which chronic inflammation of the scalp is linked to excessive sebum production and overgrowth of Malassezia fungi. These fungi break down sebum lipids, releasing pro-inflammatory unsaturated fatty acids. Lipidomic and metabolomic sebum analysis is thus essential to better understand SD. SpiderMass, an innovative ambient ionization mass spectrometry (AIMS) technology, allows for fast, direct, and non-invasive biochemical profiling of sebum. This study aimed to assess the potential of SpiderMass for evaluating the skin metabolome and lipidome in scalp SD and study the impact of an anti-SD shampoo (Kelual DS®) on the relative levels of SD-associated scalp metabolites and lipids.
methodsScalp sebum samples were obtained from 42 subjects with scalp SD enrolled in a randomized controlled clinical trial to assess the efficacy of the anti-SD shampoo. All participants used the anti-SD shampoo three times weekly for 2 weeks (intensive phase), followed by an 8-week maintenance phase in which subjects either continued to apply the anti-SD shampoo once weekly (KDS group) or switched to a neutral shampoo (control group). Sebum was collected during each study visit and analysed with SpiderMass. Additional biochemical analyses were also performed.
resultsAfter 2 weeks, SpiderMass analysis revealed a significant increase in the levels of glycerolipids and saturated fatty acids, alongside a reduction in the levels of inflammation markers such as histamine, oxylipins, and arachidonic acid. The change in lipid profile correlated with reduced Malassezia levels. During the maintenance phase, the more balanced lipid profile and lower inflammation marker levels were maintained only in the KDS group. SpiderMass findings were consistent with conventional liquid chromatography coupled to mass spectrometry (LC-MS) data.
conclusionThe anti-SD shampoo helped restore and maintain scalp lipid balance and reduce inflammation marker levels and may therefore contribute to improving skin barrier function in scalp SD. SpiderMass enabled real-time monitoring of changes in glycerolipids and inflammation markers, providing results consistent with those obtained using conventional LC-MS approaches. This reliable, powerful, non-invasive tool could be used as a rapid method for biochemical skin analysis in clinical studies, offering new insights into SD mechanisms and treatment responses. CLINICALTRIALS: GOV IDENTIFIER: NCT06578962 (retrospectively registered on 28 August 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.